Germany’s Merck expects to gradually return to organic growth this year after reporting a 14% drop in underlying earnings in 2023, which it called a “transitional” year.
Germany’s Merck expects to gradually return to organic growth this year after reporting a 14% drop in underlying earnings in 2023, which it called a “transitional” year.